摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N-diethyl-3-(p-tolyloxy)propan-1-amine

中文名称
——
中文别名
——
英文名称
N,N-diethyl-3-(p-tolyloxy)propan-1-amine
英文别名
Cambridge id 5317739;N,N-diethyl-3-(4-methylphenoxy)propan-1-amine
N,N-diethyl-3-(p-tolyloxy)propan-1-amine化学式
CAS
——
化学式
C14H23NO
mdl
——
分子量
221.343
InChiKey
NNWVAFDBMZAAAY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    16
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    N,N-diethyl-3-(p-tolyloxy)propan-1-amine间氯过氧苯甲酸 作用下, 以 二氯甲烷 为溶剂, 以97 %的产率得到N,N-diethyl-3-(p-tolyloxy)propan-1-amine oxide
    参考文献:
    名称:
    [EN] ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS
    [FR] N-OXYDES D'ÉNAMINE : SYNTHÈSE ET APPLICATION À DES PROMÉDICAMENTS SENSIBLES À L'HYPOXIE ET AGENTS D'IMAGERIE
    摘要:
    Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that are suitable for diagnosis and the treatment of diseases and disorders characterized by, associate with or which exhibit tissue hypoxia, such as, for example, solid tumors. Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds.
    公开号:
    WO2022204344A2
  • 作为产物:
    描述:
    N,N-diethyl-3-(p-tolyloxy)propan-1-amine oxide 在 四羟基二硼 作用下, 生成 N,N-diethyl-3-(p-tolyloxy)propan-1-amine
    参考文献:
    名称:
    [EN] ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS
    [FR] N-OXYDES D'ÉNAMINE : SYNTHÈSE ET APPLICATION À DES PROMÉDICAMENTS SENSIBLES À L'HYPOXIE ET AGENTS D'IMAGERIE
    摘要:
    Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that are suitable for diagnosis and the treatment of diseases and disorders characterized by, associate with or which exhibit tissue hypoxia, such as, for example, solid tumors. Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds.
    公开号:
    WO2022204344A2
点击查看最新优质反应信息

文献信息

  • Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
    申请人:Università Degli Studi Di Milano - Bicocca
    公开号:EP2161271A1
    公开(公告)日:2010-03-10
    The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).
    本发明涉及式(I)的化合物,其中R1、R2和R3如描述中所定义,以及它们的药物组合物及其在治疗表达癌基因ALK蛋白的癌症,特别是间变性大细胞淋巴瘤(ALCL)、弥漫性大B细胞淋巴瘤(DLBCL)、炎性肌纤维母细胞瘤(IMT)和非小细胞肺癌(NSCLC)中的用途。
  • PYRIMIDINE DERIVATIVES
    申请人:Kettle Jason Grant
    公开号:US20110046108A1
    公开(公告)日:2011-02-24
    The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R 1 , ring A, n, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
    这项发明涉及Formula (I)的苯甲酰胺化合物或其药用可接受的盐,其中R1、环A、n、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途,用于预防或治疗对EphB4、EphA2和/或Src激酶抑制敏感的肿瘤或其他增殖病症。
  • Carboline Derivatives Useful in the Inhibition of Angiogenesis
    申请人:MOON Young-Choon
    公开号:US20070281962A2
    公开(公告)日:2007-12-06
    In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.
    根据本发明,已经鉴定出了抑制VEGF转录后表达的化合物,并提供了它们的使用方法。在本发明的一个方面,提供了在抑制VEGF产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性方面有用的化合物。在本发明的另一个方面,提供了使用本发明中的化合物抑制VEGF产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性的方法。
  • CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS
    申请人:Moon Young-Choon
    公开号:US20100179132A1
    公开(公告)日:2010-07-15
    In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.
    根据本发明,已经鉴定出抑制VEGF在转录后表达的化合物,并提供了它们的使用方法。本发明的一方面提供了用于抑制VEGF生产、治疗实体肿瘤癌和减少血浆和/或肿瘤VEGF水平的化合物。本发明的另一方面提供了使用本发明中的化合物抑制VEGF生产、治疗癌症和减少血浆和/或肿瘤VEGF水平的方法。
  • Pyrazolopyrimidine compound and a process for preparing the same
    申请人:TANABE SEIYAKU CO., LTD.
    公开号:EP1857459A2
    公开(公告)日:2007-11-21
    The present invention provides a pyrazolopyrimidine compound of the formula [I]: wherein R1 is (A) a substituted aryl group, (B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group, (C) a substituted cyclo-lower alkyl group, (D) an optionally substituted amino group, or (E) a substituted heteroaryl group, R2 is (a) an optionally substituted heteroaryl group or (b) an optionally substituted aryl group, Y is a single bond, a lower alkylene group or a lower alkenylene group, Z is a group of the formula: -CO-, -CH2-, -SO2 or a group of the formula: Q is a lower alkylene group, and q is an integer of 0 or 1 or a pharmaceutically acceptable salt thereof, which has a small conductance potassium channel (SK channel) blocking activity and is useful as a medicament and a process for preparing the same.
    本发明提供了一种式 [I] 的吡唑嘧啶化合物: 其中 R1 是 (A) 一个取代的芳基、 (B) 任选取代的含氮脂族杂环基团、 (C) 被取代的环低烷基 (D) 任选取代的氨基,或 (E) 被取代的杂芳基、 R2 是 (a) 任选取代的杂芳基或 (b) 任选取代的芳基、 Y 是单键、低级烯基或低级烯基、 Z 是式中的一个基团:Z是式中的一个基团:-CO-、-CH2-、-SO2 或一个式中的基团: Q 是低级亚烷基,且 q 是 0 或 1 的整数,或其药学上可接受的盐,该盐具有小电导钾通道(SK 通道)阻断活性,可用作药物,以及制备该盐的工艺。
查看更多